Ramanan, Athimalaipet and Dick, Andrew D. and Jaki, Thomas and Caruso, Gianmarco and Robertson, David S. and Jones, Ashley P. and Hardwick, Ben and Drake, Sian and Balasubramaniam, Balini and Ciurtin, Coziana and Foeldvari, Ivan and Kreps, Elke O. and Leahy, Alice and May, Kristina and Quartier, Pierre and Robert, Matthieu P. and Simonini, Gabriele and Guly, Catherine and Beresford, Michael W. (2025) Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis. PEDIATRIC RHEUMATOLOGY, 23 (1): 55. ISSN , 1546-0096
Full text not available from this repository. (Request a copy)Abstract
BackgroundJuvenile idiopathic arthritis (JIA)-associated uveitis and chronic anterior uveitis in children may result in permanent sight loss. Currently, the only licensed and approved treatment for JIA-uveitis is adalimumab. However, even in patients where adalimumab may be initially effective, therapeutic response may subside for example, due to neutralising drug antibodies. Further treatment options are necessary to prevent sight loss in children with uveitis. Interleukin 17 is elevated in uveitis. Inhibition of interleukin 17 ameliorates inflammation in mouse models of uveitis. Secukinumab, an antibody which neutralizes interleukin 17 A, has been shown to be partially effective in adult uveitis. The objective of the Bayesian consensus meeting was to quantify prior expert opinion about the potential utility of secukinumab in treatment of uveitis in JIA.MethodsNine international experts in paediatric rheumatology, paediatric ophthalmology and/or paediatric uveitis took part in a structured Bayesian prior elicitation meeting.ResultsThe final consensus was that adalimumab is expected to yield a higher response rate than secukinumab (mean 0.67 vs. 0.55). The uncertainty in the response rate on secukinumab is somewhat larger than for adalimumab. The equivalent sample size for the prior distribution of adalimumab is 15.7 and 13.1 for secukinumab. The decisions based on the combined evidence would still be driven by the trial data, yet substantial enhancement of the power of the study can be expected by adding information from the equivalent of almost 30 patients.ConclusionsThe Bayesian analysis adds substantial enhancement of the power of the study and supports a head-to-head trial of adalimumab and secukinumab for JIA-associated uveitis and chronic anterior uveitis.Trial registrationISRCTN 12,427,150 Registration date 14/02/2023. EudraCT 2022-003068-26 Registration date 07/09/2022.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | METHOTREXATE; Juvenile idiopathic arthritis; Uveitis; Bayesian prior; Clinical trial; Biologics |
| Subjects: | 000 Computer science, information & general works > 004 Computer science |
| Divisions: | Informatics and Data Science > Department Machine Learning & Data Science > Lehrstuhl für Computational Statistics (Prof. Dr. Thomas Jaki) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 31 Mar 2026 09:53 |
| Last Modified: | 31 Mar 2026 09:53 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67824 |
Actions (login required)
 |
View Item |
